Navigation Links
ViroPharma er stolt over at bakke op om HAE-dag :-) 2013 og vi hjælper HAE-patienter med at fylde verden med smil
Date:5/15/2013

forårsages af en defekt i det gen, der styrer dannelsen af C1-hæmmer. C1-hæmmer opretholder den naturlige regulering i kontakt-, komplement- og fibrinolysesystemet, og hvis denne ikke reguleres, kan det medføre, at et anfald udløses og forstærkes, og at de allerede lave niveauer af endogen C1-hæmmer konsumeres hos patienter med HAE. Patienter med C1-hæmmer-mangel oplever tilbagevendende, uforudsigelige, invaliderende og potentielt livstruende anfald med hævelse, der kan berøre strube, maveregion, ansigt, ekstremiteter, urinveje og genitalier. Patienter med HAE har hvert år cirka 20 til 100 dage med uarbejdsdygtighed. Der vurderes at være mindst 10.000 personer i Europa med HAE.[1]

For mere information om HAE, klik ind på HAEi's hjemmeside (den internationale patientforening for C1-hæmmer-defekt) på  http://www.haei.org/

Om ViroPharma Incorporated

ViroPharma Incorporated er en international biofarmaceutisk virksomhed, der har engageret sig i udvikling og markedsføring af nyskabende løsninger til speciallæger, således at patienter med sygdomme, hvor der kun er ganske få eller ingen kliniske behandlingsmuligheder, kan få opfyldt deres medicinske behov. Disse sygdomme omfatter C1 esterasehæmmer-mangel, behandling af epilepsi hos børn og unge, binyreinsufficiens og infektioner med C. difficile (CDI). Vores mål er at give vores medarbejdere udbytterige karrierer, at sætte nye behandlingsstandarder for den måde, hvorpå alvorlige sygdomme behandles, samt at opbygge internationale partnerskaber med de patienter, interessegrupper og sundhedspersonale, vi betjener.

ViroPharma offentliggør med jævne mellemrum information herunder pressemeddelelser, på virksomhedens websted, der kan være vigtige for i
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. ViroPharma To Participate In The JMP Securities Healthcare Conference
4. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
5. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
6. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
7. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
8. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
9. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
11. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015 Dynatronics Corporation (NASDAQ: DYNT ) today announced ... products. This approval allows the company to sell these products in ... world. "Receiving the CE Mark represents the achievement of ... H. Cullimore Jr. , president and CEO of Dynatronics. "Over the ... China , Japan , ...
(Date:7/27/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... from institutional and accredited investors for a registered ... common stock and 3.35 million common stock purchase ...
(Date:7/27/2015)... DUBLIN , July 20, 2015 ... the addition of the "Key Pharma News ... This acquisition bolsters Gilead Sciences, burgeoning oncology ... Gilead will make further oncology deals in 2015, ... end of 2016. Key Pharma ...
Breaking Medicine Technology:Dynatronics Awarded CE Mark Approval for Its Solaris Products 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Key Pharma News Issue - Gilead will make further oncology deals in 2015 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 3
... 17, 2012  Boston Scientific Corporation (NYSE: BSX ... market launch of the Epic™ Vascular Self-Expanding Stent System.  ... in patients with iliac artery stenosis, a form of ... by insufficient blood flow.  "The Epic ...
... RARITAN, N.J., May 17, 2012 Janssen Pharmaceuticals, ... Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release ... providing pain management among adults with chronic moderate ... of the study were presented at the 31st ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 2Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 3Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 4Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 2Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 3Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 4Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 6Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 7Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 8Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 10Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 11Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 12
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association of ... Professional Woman of the Year. Ms. Baum-Lappe is recognized with this prestigious distinction ... in the country, spanning virtually every industry and profession, the National Association that ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... From Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 ... one of the first things FDA investigators will look at during an inspection. ...
(Date:7/27/2015)... ... July 27, 2015 , ... On July 14, 2015, ... Common Skin Issues,” describes common skin issues such as stretch marks , ... dermatologists to treat them. The treatment options listed include lasers, ultrasound, radio frequency, Botox, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... North Central Surgical ... , The center invites all those prospective joint-replacement patients, along with their friends ... of each month, with Monday classes (Aug 6, Sept 8 [Tue due to Labor ...
(Date:7/27/2015)... York, NY (PRWEB) , ... July 27, 2015 , ... ... American tour. He will be performing for one additional night at each of ... add promo/coupon code DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour ...
Breaking Medicine News(10 mins):Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2
... presented at the 71st Annual Scientific Meeting of ... endoscopic surgical// techniques – entering the abdomen through ... – can be successful in both bovine and ... gastroplasty for morbid obesity showed signs of initial ...
... recent study conducted at Stanford University published in American Journal ... at hand to help those// suffering from elbow tendonitis ... the possibility of a surgery to alleviate the suffering. It’s ... racquets on grass or clay courts. This ailment starts with ...
... risk of cancer is high for obese people. During studies conducted ... of weight it helped cut// down risk of some cancers, even ... liposuction was enough, as revealed in the mice study. ... cut off the superfluous fat from some mice and subjected them ...
... has been noted worldwide that a stay at any health ... infections which can complicate matters causing discomfort and// increased added ... one-tenth of patients in Canada are forced to stay longer ... during their stay there.Such infections picked up during a course ...
... nestled near the Similipal wildlife sanctuary in Orissa's Mayurbhanj ... ,"We are dying of government apathy," lamented ... are locked inside the forests." If the administration and ... well be wiped out, according to Grassroots Features. ...
... conducted by Irish Examiner/Landsdowne Market Research was an eye ... Ireland are unhappy with the maternal// services offered in the ... , ,The research has revealed that almost 63% ... two years were displeased with several aspects of the antenatal ...
Cached Medicine News:Health News:New, Minimally-Invasive Surgery for the Morbidly Obese 2Health News:New, Minimally-Invasive Surgery for the Morbidly Obese 3Health News:Tribals in the Brink of Extinction due to Malnutrition and Diseases 2Health News:Tribals in the Brink of Extinction due to Malnutrition and Diseases 3Health News:'Ire' of Irish Moms pained over maternity services in Ireland. 2
... The REFLEXION 1st MPJ IMPLANT SYSTEM ... the primary reconstruction of the 1st metatarsal ... traumatic arthritis or revision of a previous ... achieve three goals: pain relief, superior function ...
... The hands play an important part in ... impairments and rheumatic changes can cause severe ... of the finger-joint prostheses was to produce ... the natural function as nearly possible.,The cementless ...
... The OSTEOMED 3.0/4.0mm CANNULATED SCREW SYSTEM ... Orthopedic Hand surgeon and Podiatrist, can be ... fusions. The system features two simplified ... Both screw sizes utilize one unique set ...
... the lower extremity for prepping before hip or ... procedures and particularly helpful for supporting the leg ... By holding the foot/ankle in an externally rotated ... which helps eliminate the need for manual support.,The ...
Medicine Products: